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Introduction
While the last few years have witnessed a massive 
increase in new information concerning acute kidney 
injury (AKI), two areas have experienced much of this 
growth: contrast-induced acute kidney injury (CI-AKI) 
and renal replacement therapy (RRT). In early 2012, 
Kidney Disease: Improving Global Outcomes (KDIGO), a 
nonproﬁ t foundation, published the ﬁ rst international, 
interdisciplinary clinical practice guideline on AKI [1], 
which is available in its entirety on the KDIGO website 
[2]. We present here a shortened version of the guideline 
covering CI-AKI and management of RRT for AKI, and 
provide additional rationale and commentary for those 
recommendation statements that most directly impact 
the practice of critical care.
Methods
A complete and detailed description of the methods can 
been found online [3]. Th e KDIGO Co-Chairs appointed 
two Co-Chairs of the Work Group, who then assembled 
experts in several domains (nephrology, critical care 
medicine, internal medicine, pediatrics, cardiology, 
radio logy, infectious diseases, and epidemiology). Th e 
Evidence Review Team at Tufts Medical Center, Boston, 
MA, USA consisted of physician-methodologists with 
expertise in nephrology and internal medicine, and 
research associates and assistants.
Th e evidence selection, appraisal, and presentation 
have followed methodology previously described in 
KDIGO clinical practice guidelines [4]. Work Group 
members reviewed all retrieved relevant articles, data 
extraction forms, summary tables, and evidence proﬁ les 
for accuracy and completeness. Th e four major topic 
areas of interest for AKI included: deﬁ nition and classi-
ﬁ cation; prevention; pharmacologic treatment; and RRT. 
Populations of interest were those at risk for AKI (includ-
ing those after intravascular contrast-media exposure, 
aminoglycosides, and amphotericin), and patients with 
sepsis or trauma or those receiving critical care or 
undergoing cardiothoracic surgery. We excluded studies 
on AKI from rhabdomyolysis, speciﬁ c infections, and 
poisoning or drug overdose. Overall, we screened 18,385 
citations.
Outcome selection, judgments, values, and preferences
We limited outcomes to those important for decision-
making, including development of AKI, need for or 
depen dence on RRT, and all-cause mortality. When 
weighting the evidence across diﬀ erent outcomes, we 
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selected as the crucial outcome that which weighed most 
heavily in the assessment of the overall quality of 
evidence. Values and preferences articulated by the Work 
Group included: a desire to be inclusive in terms of 
meeting criteria for AKI; a progressive approach to risk 
and cost such that, as severity increased, the group put 
greater value on possible eﬀ ectiveness of strategies, but 
maintained high value for avoidance of harm; and intent 
to guide practice but not limit future research.
Grading the quality of evidence and the strength of 
recommendations
Th e grading approach followed in this guideline and the 
wording of each recommendation are adopted from the 
Grading of Recommendations Assessment, Development 
and Evaluation system [4,5]. Th e strength of each recom-
mendation is rated as level 1 (strong) or level 2 (weak or 
discretionary). In addition, each statement is assigned a 
grade for the quality of the supporting evidence: A (high), 
B (moderate), C (low), or D (very low). Furthermore, on 
topics that cannot be subjected to systematic evidence 
review, the Work Group issued statements that are not 
graded which hopefully will provide general guidance 
based on clinical experience.
Th e Grading of Recommendations Assessment, 
Develop ment and Evaluation system is best suited to 
evaluate evidence on comparative eﬀ ectiveness. Some of 
our most important guideline topics involve diagnosis 
and staging of AKI, and here the Work Group chose to 
provide ungraded statements. Th ese statements are 
indirectly supported by evidence on risk relationships 
and resulted from unanimous consensus of the Work 
Group and should not be viewed as weaker than graded 
recommendations.
Recommendations and rationale
Th e Work Group developed 61 graded recommendation 
statements and 26 ungraded statements. Th e six major 
domains are: (A) deﬁ nition and staging; (B) risk 
assessment; (C) evalu ation and general management; (D) 
prevention and treat ment; (E) CI-AKI; and (F) RRT for 
AKI. Domains (E) and (F) are presented here, while 
domains (A) through (D) are discussed in the preceding 
review.
E. Contrast-induced acute kidney injury
Classifi cation and risk assessment
Pending the validation of future biomarkers that would 
allow a more straightforward comparison and integration 
of CI-AKI in the overall framework of AKI, we suggest 
that the same criteria using the changes in serum 
creatinine (SCr) concentrations and urine output be used 
as for the other forms of AKI. A CI-AKI Consensus 
Working Panel agreed that the risk of CI-AKI becomes 
clinically important when the baseline SCr concentration 
is ≥1.3  mg/dl (≥115  μmol/l) in men and ≥1.0  mg/dl 
(≥88.4  μmol/l) in women, equivalent to an estimated 
glomerular ﬁ ltration rate <60 ml/minute per 1.73 m2 [6]. 
However, Bruce and colleagues showed that the incidence 
of true AKI became signiﬁ cant only between controls 
and contrast-media administered patients from a baseline 
SCr concentration >1.8 mg/dl (>159 μmol/l) onward [7]. 
Th e CI-AKI Consensus Working Panel recommended 
that precautions to reduce the risk should be imple-
mented in patients with a baseline estimated glomerular 
ﬁ ltration rate <60 ml/minute per 1.73 m2 [6]. In light of 
more recent information, this threshold could probably 
be lowered to 45 ml/minute per 1.73 m2. Table 1 provides 
a CI-AKI risk-scoring model for percutaneous coronary 
intervention.
In patients at increased risk for CI-AKI, the risks and 
beneﬁ ts of iodinated contrast-media administration 
should be discussed with the radiologist. One should 
note that magnetic resonance imaging with gadolinium 
contrast is not a safe alternative for many patients with 
pre-existing renal dysfunction. New labeling describes 
the risk for nephrogenic systemic ﬁ brosis following 
exposure to gadolinium in patients with a glomerular 
ﬁ ltration rate <30 ml/minute per 1.73 m2 and in patients 
with AKI of any severity due to hepatorenal syndrome or 
in the perioperative liver transplantation period. 
Additional recommendations were recently proposed by 
Perazella [8] and were endorsed by the Work Group.
E1: Deﬁ ne and stage AKI after administration of 
intravascular contrast media as per 
Recommendations A1 and A2 (not graded).
E1.1:  In individuals who develop changes in kidney 
function after administration of intravascular 
contrast media, evaluate for CI-AKI as well as 
for other possible causes of AKI (not graded).
E2:  Assess the risk for CI-AKI and, in particular, 
screen for pre-existing impairment of kidney 
function in all patients who are considered for a 
procedure that requires intravascular 
(intravenous or intraarterial) administration of 
iodinated contrast medium (not graded).
Contrast type and volume
Th e correlation between the volume of contrast media 
administered and the risk of CI-AKI has been recognized 
[10]. A recent study by Nyman and colleagues in patients 
undergoing coronary angioplasty calculated the proba-
bility of CI-AKI (SCr rise >0.5  mg/dl (>44.2  μmol/l) or 
oliguria/anuria) at various estimated glomerular ﬁ ltration 
rate levels based on grams of iodine/estimated glomeru-
lar ﬁ ltration rate ratios of 1:2, 1:1, 2:1, and 3:1 [11]. At a 
ratio <1 the risk of CI-AKI was 3%, while it was 25% at a 
ratio ≥1. Th is study and other preliminary studies 
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indi cate that a ratio <1 may be relatively safe in a patient 
without multiple risk factors [11-13].
Both the review by Goldfarb and colleagues [14] and 
the meta-analysis from Barrett and Carlisle combining 24 
randomized studies [15] suggest that the risk of CI-AKI is 
similarly low with high-osmolar and low-osmolar agents 
among otherwise stable patients with normal renal 
function. In contrast to high-osmolar contrast media, 
however, low-osmolar contrast media are less nephro toxic 
in patients with pre-existing kidney function impair ment.
Among low and iso-osmolar contrast, of eight studies 
comparing contrast media [16-23] some showed superi-
ority of iso-osmolar contrast media (iodixanol) compared 
with iohexol [16] and iopromide [21]. Th ere was no 
diﬀ erence when iodixanol was compared with iopamidol 
[18,23], iopro mide [17,19], and ioversal [22]. A recent 
meta-analysis [24] analyzed studies comparing iodixanol 
with low-osmolar contrast media. Th e pooled relative 
risk was 0.68 (95% conﬁ dence interval  = 0.46 to 1.01; 
P  =  0.06). Iodixanol is thus not associated with a 
signiﬁ cantly reduced risk of CI-AKI compared with the 
low-osmolar contrast media pooled together. In patients 
with de creased kidney function, however, iodixanol is 
associated with a reduced risk of CI-AKI compared with 
iohexol.
For iodixanol versus ioxaglate, two studies fulﬁ lled our 
inclusion criteria; one study showed a superiority of 
iodixanol versus ioxaglate [25], but this was not con-
ﬁ rmed in the study by Mehran and colleagues that found 
no diﬀ erence between these two contrast agents [26]. 
Based on this evi dence and the most recent meta-analysis 
of the studies comparing iso-osmolar versus low-osmolar 
contrast media [24], the Work Group found no evidence 
to recommend a preference for either type of agent.
E3:  Consider alternative imaging methods in 
patients at increased risk for CI-AKI (not 
graded).
E4: Use the lowest possible dose of contrast medium 
in patients at risk for CI-AKI (not graded).
E5: We recommend using either iso-osmolar or 
low-osmolar iodinated contrast media, rather 
than high-osmolar iodinated contrast media, in 
patients at increased risk of CI-AKI (Grade 1B).
Volume expansion
Sodium bicarbonate solutions have been tested in the 
prevention of CI-AKI in comparison with isotonic saline, 
either with or without N-acetylcysteine (NAC). A number 
of systematic reviews on the role of sodium bicarbonate 
compared with isotonic saline in the prevention of CI-
AKI are available [27-33]. Th e most recent and probably 
the most complete systematic review analyzed random-
ized controlled trials (RCTs) of intravenous sodium 
bicarbonate that prespeciﬁ ed the outcome of CI-AKI as a 
25% increase in baseline SCr concentration or an absolute 
increase of 0.5 mg/dl (44.2 μmol/l) after contrast-media 
administration [33]. Twenty-three published and 
unpublished trials with infor mation on 3,563 patients 
and 396 CI-AKI events were included. Th e pooled 
relative risk was 0.62 (95% conﬁ dence interval = 0.45 to 
0.86), with evidence of signiﬁ cant heterogeneity across 
studies due to the diﬀ er ence in the estimates between 
published and unpublished studies. Meta-regression 
showed that small, poor-quality studies that assessed 
outcomes soon after contrast-media administration were 
more likely to suggest the beneﬁ t of bicarbonate (P <0.05 
for all). No clear eﬀ ects of treatment on the risk for 
dialysis, heart failure, and total mortality were identiﬁ ed.
One should note that mixing of the bicarbonate 
solution is often done at the bedside or in the hospital 
pharmacy, with the possibility for errors leading to the 
infusion of a hypertonic bicarbonate solution. Th e 
potential for harm from dosing errors and the added 
burden from this bedside preparation have to be taken 
into account in clinical practice when making a choice 
between using bicarbonate rather than standard isotonic 
saline solutions. Taken together, the Work Group con-
cluded that there is a possible but inconsistent beneﬁ t of 
bicarbonate solutions based on overall moderate-quality 
evidence. Th e potential of harm and the burden for 
preparing the bicarbonate solutions led the Work Group 
not to express a preference for or against one solution 
(isotonic saline or isotonic bicarbonate). Either solution 
can therefore be used for the prevention of CI-AKI. In 
any case, volume expansion should be intravenous. Oral 
volume expansion may have some beneﬁ t, but there is 
insuﬃ  cient evidence to show it is as eﬀ ective as 
intravenous volume expansion [34].
Table 1. Contrast-induced acute kidney injury risk-scoring 
model for percutaneous coronary intervention
Risk factor Integer score (calculated)a
Hypotension 5
Intra-aortic balloon pump 5
Congestive heart failure 5
Age >75 years 4
Anemia 3
Diabetes 3
Contrast-media volume 1 per 100 ml
SCr >1.5 mg/dl (>132.6 μmol/l) or  4
 eGFR <60 ml/minute per 1.73 m2 2 for 40 to 60 ml/minute per 
  1.73 m2, 4 for 20 to 39 ml/minute 
  per 1.73 m2, 6 for <20 ml/minute 
  per 1.73 m2
eGFR, estimated glomerular fi ltration rate; SCr, serum creatinine. Reprinted from 
[9] with permission from the American College of Cardiology Foundation. aLow 
risk, cumulative score <5; high risk, cumulative score >16.
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E6: We recommend intravenous volume expansion 
with either isotonic sodium chloride or sodium 
bicarbonate solutions, rather than no 
intravenous volume expansion, in patients at 
increased risk for CI-AKI (Grade 1A).
E7: We recommend not using oral ﬂ uids alone in 
patients at increased risk for CI-AKI (Grade 
1C).
Other interventions to reduce contrast-induced AKI
Many, but not all, studies have shown NAC to have a 
protective eﬀ ect on CI-AKI when administered before 
the onset of renal insult (for a review, see McCullough 
[35]). In addition, NAC is inexpensive and appears to be 
safe, although it may have some detrimental eﬀ ects on 
myocardial and coagulation function [36-38]. Th e safety 
of NAC should further be amended, particularly when 
high intravenous doses are used, as in some of the RCTs 
in CI-AKI. When prospectively studied in acetaminophen 
poisoning, intravenous NAC produced anaphylactoid 
reactions in up to 48% of participants [39]. Although 
most of these reactions were mild, at least one death has 
been reported in a patient with asthma [40]. Based on the 
existing evidence, the overall beneﬁ t of NAC is not 
consistent or overwhelming. On the other hand, oral 
NAC has a low risk of adverse events and usually a low 
cost.
Th e eﬃ  cacy of theophylline in preventing CI-AKI has 
been addressed by a systematic review and meta-analysis 
in 2005 [41], and by another meta-analysis in 2008 [42]. 
Both meta-analyses indicated a nonsigniﬁ cant trend 
toward a renoprotective eﬀ ect of theophylline prophy-
laxis but the overall beneﬁ t was small and ﬁ ndings were 
inconsistent across studies. Th e beneﬁ t tended to be less 
marked in patients receiving iso-osmolar, nonionic 
contrast media, and in patients undergoing a predeﬁ ned 
saline protocol. Two prospective randomized trials of 
fenoldopam for CI-AKI showed negative results [43,44].
Contrast media can be eﬃ  ciently removed from blood 
by intermittent hemodialysis (IHD), and a single session 
eﬀ ectively removes 60 to 90% of contrast media [45,46]. 
On the basis of these observations, several studies have 
explored the prophylactic value of IHD in patients at high 
risk for AKI, but most of these studies have not demon-
strated a reduced incidence of CI-AKI [46,47]. A recent 
meta-analysis of studies using periprocedural extra-
corporeal blood puriﬁ cation techniques concluded that 
such treatments did not decrease the incidence of CI-
AKI [45].
E8:  We suggest using oral NAC, together with 
intravenous isotonic crystalloids, in patients at 
increased risk of CI-AKI (Grade 2D).
E9: We suggest not using theophylline to prevent 
CI-AKI (Grade 2C).
E10: We recommend not using fenoldopam to 
prevent CI-AKI (Grade 1B).
E11:  We suggest not using prophylactic IHD or 
hemoﬁ ltration for contrast-media removal in 
patients at increased risk for CI-AKI (Grade 
2C).
F. Renal replacement therapy for treatment of AKI
Initiating and discontinuing RRT for patients with AKI
While no RCTs exist for dialysis for life-threatening 
indications, it is widely accepted that patients with severe 
hyperkalemia, severe acidosis, pulmonary edema, and 
uremic complications should be dialyzed emergently. In 
the absence of kidney function, and when therapeutic 
measures that promote the intracellular shift of potas-
sium (such as correction of acidosis with bicar bonate, 
glucose and insulin infusion, and β2 agonists) are 
exhausted, an excess of potassium can only be eliminated 
with RRT.
Provision of acute RRT to children requires special 
consideration. Th e epidemiology of pediatric AKI has 
changed from primary kidney disease in the 1980s to 
injury resulting from another systemic illness or its treat-
ment (for example, sepsis and nephrotoxic medications) 
[48,49]. Newborns with inborn errors of metabolism who 
do not respond to dietary and pharmacologic manage-
ment require expeditious dialytic removal of ammonia to 
decrease the risk of death and long-term neurologic 
dysfunction [50], and infants who receive surgical correc-
tion of congenital heart disease often receive peritoneal 
dialysis early after cardiopulmonary bypass to prevent 
ﬂ uid overload and/or minimize the proinﬂ ammatory 
response. Finally, children develop multiorgan dys func-
tion very rapidly in their ICU course, with the maximal 
organ dysfunction occurring with 72 hours and mortality 
occurring within 7  days of ICU admission, respectively 
[51,52]. In both children and adults, there fore, the issue 
of timing of dialysis initiation is critically important. 
Fluid overload has emerged as a signiﬁ cant factor asso-
ciated with mortality in children as well as adults with 
AKI requiring RRT, although the physiological link 
between increasing percentage volume overload and 
mortality is not completely clear [53-59].
Many, but not all, patients requiring RRT will recover 
enough function not to require long-term RRT [60-62]. 
Th e mean duration of RRT in two recent large RCTs was 
12 to 13 days [63,64]. Daily assessment of both intrinsic 
kidney function and the ongoing appropriateness of RRT 
consistent with the goals of therapy for the patient is 
therefore required. Analysis from the BEST KIDNEY 
study showed that continuous renal replacement therapy 
(CRRT) was withdrawn in 13% of the patients, 
representing 29% of those who died while on CRRT and 
21% of all nonsurvivors [65].
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Only one RCT has evaluated the potential role of 
diuretics in resolving AKI in patients receiving RRT [66]. 
In this trial, there were no diﬀ erences in need for 
repeated continuous venovenous hemoﬁ ltration or renal 
recovery during the ICU or hospital stay. An obser-
vational study of discontinuation of RRT also found no 
diﬀ erence in diuretic use between patents with successful 
or unsuccessful discontinuation of IHD [67].
F1:  Initiate RRT emergently when life-threatening 
changes in ﬂ uid, electrolyte, and acid–base 
balance exist (not graded).
F2:  Consider the broader clinical context, the 
presence of conditions that can be modiﬁ ed 
with RRT, and trends of laboratory tests – 
rather than single blood urea nitrogen and 
creatinine thresholds alone – when making the 
decision to start RRT (not graded).
F3: Discontinue RRT when it is no longer required, 
either because intrinsic kidney function has 
recovered to the point that it is adequate to 
meet patient needs, or because RRT is no longer 
consistent with the goals of care (not graded).
F4: We suggest not using diuretics to enhance 
kidney function recovery or to reduce the 
duration or frequency of RRT (Grade 2B).
Anticoagulation for RRT
A recent meta-analysis of 11 RCTs comparing unfrac-
tionated heparin with low-molecular-weight heparin in 
chronic IHD concluded that both are equally safe in 
terms of bleeding complications and equally as eﬀ ective 
in preventing extracorporeal thrombosis [68]. Mainly 
because of the convenience of using a single bolus 
injection at the start of IHD, the reduced risk of heparin-
induced thrombo cytopenia (HIT), and long-term side 
eﬀ ects such as abnormal serum lipids, osteoporosis, and 
hypoaldo ster o n ism, the European practice guideline for 
prevention of dialyzer clotting suggests using low-
molecular-weight heparin rather than unfractionated 
heparin in chronic dialysis patients [69]. Many European 
centers have extrapolated this to IHD for AKI, although 
studies in this setting are lacking.
Crossover comparison of prostacyclin with low-
molecular-weight heparin in chronic dialysis patients 
shows reduced eﬃ  ciency [70]. A small trial showed 
reduced bleeding complications compared with low-dose 
heparin, but at the expense of slightly more premature 
terminations [71]. Additional drawbacks are systemic 
hypotension and the high costs. Th e routine use of 
alternative anticoagulants therefore cannot be recom-
mended in patients with AKI.
Five randomized trials have compared citrate with 
heparins during CRRT [72-76]. For ethical reasons, these 
trials were performed in patients without increased 
bleeding risk. Overall, citrate appears to be superior to 
heparin in terms of either ﬁ lter survival or patient out-
comes or both. In the largest and most recent randomized 
trial, 200 patients treated with postdilution continuous 
venovenous hemoﬁ ltration were randomized to citrate or 
to nadroparin, a low-molecular-weight heparin [76]. 
Safety was signiﬁ cantly better in the citrate group while 
circuit survival did not signiﬁ cantly diﬀ er. Rather sur-
prisingly, an improved renal recovery and an improved 
hospital survival were also found in the citrate group. 
Th is obser vation requires further investigation. Meta-
bolic compli ca tions were infrequent in these randomized 
trials. In observational trials, the most frequent metabolic 
compli cation with citrate is metabolic alkalosis, occur-
ring in up to 50% of the patients [77-79]. In recently 
published surveys or large clinical trials, the use of 
regional citrate anticoagulation is still limited to 0 to 20% 
of the patients/treatments [63,64,80]. Th e Work Group 
therefore only recommends the use of citrate for 
anticoagulation during CRRT in patients that do not have 
shock or severe liver failure, and in centers that have an 
established protocol for citrate anticoagulation.
Unfractionated heparin still remains the most widely 
used anticoagulant during CRRT [63,64,80], mostly 
administered as a preﬁ lter infusion, with large variability 
in the administered doses. When choosing a dose of 
heparin, the clinician should realize that the relationship 
between the heparin dose, the activated partial thrombo-
plastin time, ﬁ lter survival, and bleeding complications is 
not straightforward [81-87], but it is common practice to 
measure the activated partial thromboplastin time for 
safety reasons and to adapt the target to the bleeding risk 
of the patient. No advantage has been found for low-
molecular-weight heparin for CRRT [83]. In one study, 
daily costs, including the coagulation assays, were 10% 
higher with dalteparin [88]. Alternative anticoagulants 
include the protease inhibitor nafamostat and the platelet 
inhibitors, prostacyclin and analogues. Both have a short 
half-life and a low molecular weight, with the theoretical 
advantage of extracorporeal elimination and reduced 
systemic anticoagulation. Nafamostat is a protease inhi-
bi tor that is mainly used in Japan and is not available in 
the USA or Europe. Small observational trials in chronic 
dialysis patients with increased bleeding risk suggest a 
reduced bleeding incidence [89-91]. Concerns with 
nafamostat include the absence of an antidote, and side 
eﬀ ects such as anaphylaxis, hyperkalemia, and bone 
marrow suppression [92-94].
A few small trials showed improved ﬁ lter survival during 
CRRT when adding prostaglandins to heparin compared 
with heparin alone [95-97]. However, prosta glandins 
appear to have a limited eﬃ  cacy when used alone, induce 
systemic hypotension [98,99], and are expensive. Th eir use 
during CRRT therefore cannot be recommended.
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We suggest performing RRT without anticoagulation in 
patients with increased bleeding risk. A possible excep-
tion can be made for patients who do not have 
contraindications for citrate. With regard to the diagnosis 
and management of HIT, we refer to the recent guideline 
of the American College of Chest Physicians [100] and 
the European best practice guideline on chronic dialysis 
[69]. Alternative nonheparin anticoagulants in patients 
with strong suspicion of HIT are recommended. Candi-
dates are the direct thrombin inhibitors lepirudin, 
argatroban, or bivaluridin, or the antithrombin-depen-
dent activated factor X inhibitors danaparoid or fonda-
parinix. Pharmacokinetic data and dosing guidelines for 
these alternative anticoagulants have been published for 
IHD [101,102] and CRRT [103].
F5: In a patient with AKI requiring RRT, base the 
decision to use anticoagulation for RRT on 
assessment of the patient’s potential risks and 
beneﬁ ts from anticoagulation (see Figure 1) (not 
graded).
F5.1: We recommend using anticoagulation during 
RRT in AKI if a patient does not have an 
increased bleeding risk or impaired coagulation 
and is not already receiving systemic 
anticoagulation (Grade 1B).
F6:  For patients without an increased bleeding risk 
or impaired coagulation and not already 
receiving eﬀ ective systemic anticoagulation, we 
suggest the following:
F6.1: For anticoagulation in intermittent RRT, we 
recommend using either unfractionated heparin 
or low-molecular-weight heparin, rather than 
other anticoagulants (Grade 1C).
F6.2: For anticoagulation in CRRT, we suggest using 
regional citrate anticoagulation rather than 
heparin in patients who do not have 
contraindications for citrate (Grade 2B).
F6.3: For anticoagulation during CRRT in patients 
who have contraindications for citrate, we 
suggest using either unfractionated heparin or 
low-molecular-weight heparin, rather than 
other anticoagulants (Grade 2C).
F7: For patients with increased bleeding risk who 
are not receiving anticoagulation, we suggest 
the following for anticoagulation during RRT:
F7.1: We suggest using regional citrate 
anticoagulation, rather than no anticoagulation, 
during CRRT in a patient without 
contraindications for citrate (Grade 2C).
F7.2: We suggest avoiding regional heparinization 
during CRRT in a patient with increased risk of 
bleeding (Grade 2C).
F8:  In a patient with HIT, all heparin must be 
stopped and we recommend using direct 
thrombin inhibitors (such as argatroban) or 
Factor Xa inhibitors (such as danaparoid or 
fondaparinux) rather than other or no 
anticoagulation during RRT (Grade 1A).
F8.1: In a patient with HIT who does not have severe 
liver failure, we suggest using argatroban rather 
than other thrombin or Factor Xa inhibitors 
during RRT (Grade 2C).
Vascular access and dialysis membranes
Both the Centers for Disease Control guidelines for 
prevention of catheter-related infections and the Kidney 
Disease Outcomes Quality Initiative guideline for vas cu-
lar access in chronic dialysis patients recommend using a 
cuﬀ ed catheter for dialysis if a prolonged (for example, >1 
to 3  weeks) period of temporary access is anticipated 
[104,105]. In two recent large randomized trials, the 
mean duration of RRT for AKI was 12 to 13 days [63,64]. 
Th is duration probably does not justify the burden of an 
initial tunneled catheter in all patients with AKI receiving 
RRT. Rather, selected use of tunneled catheters in 
patients who require prolonged RRT is warranted.
Although generally associated with the lowest rate of 
infectious complications, the Centers for Disease Control 
guideline as well as the Kidney Disease Outcomes Quality 
Initiative guideline recommend avoiding the subclavian 
vein for RRT access [104,105], because this may lead to 
central vein stenosis and jeopardize subsequent perma-
nent access. Recirculation has been shown to be more 
frequent in femoral than subclavian or jugular dialysis 
catheters, especially with shorter femoral cathe ters 
[106,107]. Catheter insertion should be per formed with 
strict adherence to infection-control policies, including 
maximal sterile barrier precautions and chlorhexidine 2% 
skin antisepsis [105,108,109].
Two meta-analyses exploring the role of real-time two-
dimensional ultrasound for central vein cannulation 
concluded that, compared with the landmark method, 
ultrasound-guided venous access increases the proba-
bility of successful catheter placement and reduces the 
risk of complications, the need for multiple catheter 
placement attempts, and the time required for the proce-
dure. Th e advantage appears most pronounced for the 
jugular vein, whereas the evidence is scarce for the 
subclavian and femoral vein [110,111]. Subsequent large 
randomized trials have conﬁ rmed the superiority of 
ultrasound guidance [112,113]. Th e Kidney Disease 
Outcomes Quality Initiative guideline for vascular access 
also recommends using ultrasound-assisted insertion 
[104].
A postprocedural chest radiograph is conventionally 
performed to conﬁ rm the correct position of the catheter 
and to assess for potential complications. Although this 
procedure has been debated after uneventful placement 
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Figure 1. Flow-chart summary of recommendations. Heparin includes low-molecular-weight heparin or unfractionated heparin. CRRT, 
continuous renal replacement therapy; RRT, renal replacement therapy.
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of a central venous catheter, the high blood ﬂ ows used 
during RRT and the administration of anticoagulants 
necessitate conﬁ rming the correct position before 
initiating dialysis therapy [104]. For detailed instructions 
on catheter care, the reader is referred to published 
guidelines [104,105,108,109]. Th ese guidelines also recom-
mend not using dialysis catheters for applications other 
than RRT, except under emergency circumstances [105]. 
Th e Centers for Disease Control, the National Health 
Service, and the Infectious Diseases Society of America 
guidelines strongly recommend against routinely using 
antibiotic lock solutions in the central venous catheter, 
because of their potential to promote fungal infections, 
antimicro bial resistance, and systemic toxicity 
[105,108,109].
A recent meta-analysis of 10 randomized trials or 
quasi-RCTs in 1,100 patients could not establish any 
advantage for biocompatible or high-ﬂ ux membranes 
[114]. Of note, the authors chose to include modiﬁ ed 
cellulose mem branes in the bioincompatible group, 
although other investigators consider modiﬁ ed cellulosic 
membranes to be biocompatible. When comparing the 
synthetic membranes with cuprophane, there was a trend 
towards reduced mortality with the synthetic mem-
branes. Th is meta-analysis also did not assess the side 
eﬀ ects of diﬀ erent membrane compositions on more 
proximal, temporal associations, such as acute hypo-
tension or fever. As a result, the Work Group agrees with 
the authors’ conclusion that the use of either a bio com-
patible or modiﬁ ed cellulose acetate membrane appears 
to be appropriate.
F9:  We suggest initiating RRT in patients with AKI 
via an uncuﬀ ed nontunneled dialysis catheter, 
rather than a tunneled catheter (Grade 2D).
F10:  When choosing a vein for insertion of a dialysis 
catheter in patients with AKI, consider these 
preferences (not graded):
• ﬁ rst choice: right jugular vein;
• second choice: femoral vein;
• third choice: left jugular vein; 
• last choice: subclavian vein with preference 
for the dominant side.
F11:  We recommend using ultrasound guidance for 
dialysis catheter insertion (Grade 1A).
F12:  We recommend obtaining a chest radiograph 
promptly after placement and before ﬁ rst use of 
an internal jugular or subclavian dialysis 
catheter (Grade 1B).
F13:  We suggest not using topical antibiotics over 
the skin insertion site of a nontunneled dialysis 
catheter in ICU patients with AKI requiring 
RRT (Grade 2C).
F14:  We suggest not using antibiotic locks for 
prevention of catheter-related infections of 
nontunneled dialysis catheters in AKI requiring 
RRT (Grade 2C).
F15:  We suggest using dialyzers with a biocompatible 
membrane for IHD and CRRT in patients with 
AKI (Grade 2C).
Modality of RRT for AKI
Several RCTs have compared CRRT with IHD in AKI 
patients. Th e most inclusive meta-analysis was performed 
by the Cochrane Collaboration, analyzing 15 RCTs in 
1,550 AKI patients. Th is analysis concluded that out-
comes were not diﬀ erent for critically ill AKI patients 
treated with CRRT versus IHD for hospital mortality, 
ICU mortality, length of hospitalization, and renal 
recovery (free of dialysis on discharge) in survivors [115]. 
Comparable results have been reported by other meta-
analyses [116,117]. Most trials excluded patients with 
hypotension or maximized eﬀ orts to improve the hemo-
dynamic tolerance of IHD. Th e high rate of crossover 
between the treatment modalities also complicates the 
interpretation of the results.
Many clinicians prefer CRRT in critically ill AKI 
patients with severe hemodynamic instability, because of 
better hemodynamic tolerance due to the slower ﬂ uid 
removal and the absence of ﬂ uid shifts induced by rapid 
solute removal. Th e Cochrane meta-analysis, however, 
could not establish a diﬀ erence in the number of patients 
with hemodynamic instability (however deﬁ ned) or with 
hypotension. On the contrary, the mean arterial pressure 
at the end of the treatment was signiﬁ cantly higher with 
CRRT than with IHD and the number of patients 
requiring escalation of vasopressor therapy was signiﬁ -
cantly lower with CRRT compared with IHD [115].
Slow low-eﬃ  ciency dialysis has been proposed as an 
alternative to other forms of RRT and is used in many 
centers worldwide for logistical reasons. A recent review 
summarizes the results obtained with slow low-eﬃ  ciency 
dialysis in several studies and discusses in detail the 
technical aspects of this dialysis method [118]. However, 
randomized trials comparing IHD with slow low-
eﬃ  ciency dialysis have not been performed. Also, clinical 
experience is far more limited with slow low-eﬃ  ciency 
dialysis compared with CRRT, and very few randomized 
studies have compared slow low-eﬃ  ciency dialysis to 
CRRT.
In a patient with acute brain injury, IHD may worsen 
neurological status by compromising cerebral perfusion 
pressure. Th is may be the result of a decrease of mean 
arterial pressure (dialysis-induced hypotension) or an 
increase of cerebral edema and intracranial pressure 
(dialysis disequilibrium), and may jeopardize the poten-
tial for neurologic recovery. Dialysis disequilibrium 
results from the rapid removal of solutes, resulting in 
intracellular ﬂ uid shifts. Both hypotension and 
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disequili brium can be avoided by the slow progressive 
removal of ﬂ uids and solutes that occurs during CRRT 
[119]. Small observational trials and case reports in 
patients with intracranial pressure monitoring indeed 
reported increases in intracranial pressure with IHD 
[120,121]. Using computed tomography scans to measure 
brain density, Ronco and colleagues [122] showed an 
increase of brain water content after IHD whereas no 
such changes were observed after CRRT.
F16:  Use continuous and intermittent RRT as 
complementary therapies in AKI patients (not 
graded).
F17:  We suggest using CRRT, rather than standard 
intermittent RRT, for hemodynamically 
unstable patients (Grade 2B).
F18:  We suggest using CRRT, rather than 
intermittent RRT, for AKI patients with acute 
brain injury or other causes of increased 
intracranial pressure or generalized brain 
edema (Grade 2B).
Dialysate and replacement fl uid
Use of bicarbonate as a buﬀ er in the dialysate or replace-
ment ﬂ uid of AKI patients results in better correction of 
acidosis, lower lactate levels, and improved hemo-
dynamic tolerance [123,124]. Th ese eﬀ ects are most pro-
nounced in patients with circulatory problems and in 
those with liver dysfunction. An international quality 
standard for dialysis ﬂ uid is in preparation by the 
International Society for Standardization. Until inter-
national standards are in place, we recommend that 
dialysis ﬂ uids and replacement ﬂ uids in patients with 
AKI, at a minimum, comply with American Association 
of Medical Instrumentation standards for bacteria and 
endotoxins [125-127]. When local standards exceed 
American Association of Medical Instrumentation 
standards, local standards should be followed.
F19:  We suggest using bicarbonate, rather than 
lactate, as a buﬀ er in dialysate and replacement 
ﬂ uid for RRT in patients with AKI (Grade 2C).
F20:  We recommend using bicarbonate, rather than 
lactate, as a buﬀ er in dialysate and replacement 
ﬂ uid for RRT in patients with AKI and 
circulatory shock (Grade 1B).
F21: We suggest using bicarbonate, rather than 
lactate, as a buﬀ er in dialysate and replacement 
ﬂ uid for RRT in patients with AKI and liver 
failure and/or lactic acidemia (Grade 2B).
F22:  We recommend that dialysis ﬂ uids and 
replacement ﬂ uids in patients with AKI, at a 
minimum, comply with American Association 
of Medical Instrumentation standards regarding 
contamination with bacteria and endotoxins 
(Grade 1B).
Intensity of RRT
Several clinical inves tigations have shown that the actual 
delivered dose of RRT in AKI patients is frequently 
smaller than the prescribed dose, and is even smaller 
than the recommended minimum for chronic kidney 
disease patients [128-132]. Impediments to adequate 
dose delivery were hemodynamic instability, patient size, 
access problems, technical problems, need for patient 
transportation, and early ﬁ lter clotting. In determining a 
prescription of RRT it is mandatory to consider 
parameters other than small-solute clearance, such as 
patients’ ﬂ uid balance, acid–base and electrolyte homeo-
stasis, and nutrition, among others, as possible compo-
nents of an optimal RRT dose. In fact, positive ﬂ uid 
balance appears to be an independent risk factor for 
mortality in AKI patients [133].
Th ere are only two adequately designed and executed 
RCTs testing intermittent or extended RRT doses in AKI 
[64,134]. Neither study showed improvement in mortality 
or renal recovery when the dialysis dose was increased, 
either by increasing the clearance × time/volume (Kt/V) 
ratio above 3.9  weekly or by achieving a plasma urea 
target below 90  mg/dl (15  mmol/l) in AKI patients. 
Consistent with data on the dose of IHD in chronic 
kidney disease [135] and consistent with the lower-dose 
arm in the Acute Renal Failure Trial Network study [64], 
however, we recom mend a thrice-weekly Kt/V ratio of 
1.3 or a weekly Kt/V ratio of 3.9 for IHD in AKI. Similarly, 
there are now consistent data from two large multicenter 
trials showing no beneﬁ ts of increasing CRRT doses in 
AKI patients above eﬄ  uent ﬂ ows of 20 to 25 ml/kg/hour 
[63,64]. In clinical practice, in order to achieve a delivered 
dose of 20 to 25 ml/kg/hour, it is generally necessary to 
prescribe in the range of 25 to 30 ml/kg/hour and to 
minimize interruptions in CRRT.
F23:  Th e dose of RRT to be delivered should be 
prescribed before starting each session of RRT 
(not graded). We recommend frequent 
assessment of the actual delivered dose in order 
to adjust the prescription (Grade 1B).
F24:  Provide RRT to achieve the goals of electrolyte, 
acid–base, solute, and ﬂ uid balance that will 
meet the patient’s needs (not graded).
F25:  We recommend delivering a Kt/V ratio of 3.9 
per week when using intermittent or extended 
RRT in AKI (Grade 1A).
F26:  We recommend delivering an eﬄ  uent volume of 
20 to 25 ml/kg/hour for CRRT in AKI (Grade 
1A). Th is will usually require a higher 
prescription of eﬄ  uent volume (not graded).
Ab breviations
AKI, acute kidney injury; CI-AKI, contrast-induced acute kidney injury; 
CRRT, continuous renal replacement therapy; HIT, heparin-induced 
thrombocytopenia; ICU, intensive care unit; IHD, intermittent hemodialysis; 
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KDIGO, Kidney Disease: Improving Global Outcomes; Kt/V, clearance×time/
volume; NAC, N-acetylcysteine; RCT, randomized controlled trial; RRT, renal 
replacement therapy; SCr, serum creatinine.
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